Drug combinations: From laboratory to practice

References

1. • Chou T-C
   • Talalay P
   Analysis of combined drug effects: a new look at a very old problem.
   Trends Pharmacol Sci. 1983; 4: 450-454
   • Google Scholar
2. • Chou T-C
   The median-effect principle and the combination index for quantitation of synergism and antagonism.
   in: Chou T-C Rideout D Synergism and antagonism in chemotherapy. Academic Press, San Diego1991: 61-102
   • Google Scholar
3. • Chou T-C
   • Rideout D
   • Chou JH
   • Bertino JR
   Chemotherapeutic synergism, potentiation and antagonism. 2nd ed. Encyclopedia of human biology. vol 2. Academic Press, San Diego1997: 675-683
   • Google Scholar
4. • Chou T-C
   • Motzer RJ
   • Tong Y
   • Bosl GJ
   Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against teratocarcinoma cell growth: a rational approach to clinical protocol design.
   J Natl Cancer Inst. 1994; 86: 1517-1524
   • Google Scholar
5. • Bertino JR
   • Chou T-C
   Chemotherapy: synergism and antagonism. 2nd ed. Encyclopedia of cancer. vol 1. Academic Press, San Diego1997: 368-379
   • Google Scholar
6. • Guo J
   • Reidenberg MM
   Inhibition of 11-β hydroxysteroid dehydrogenase by bioflavonoids and their interaction with furosemide and gossypol.
   J Lab Clin Med. 1998; 131: 32-38
   • Google Scholar
7. Permuterm Subject Index, Science Citation Index. Institute for Scientific Information, Philadelphia1997
   • Google Scholar
8. • Goldin A
   • Mantel N
   The employment of combinations of drugs in the chemotherapy of neoplasia: a review.
   Cancer Res. 1957; 17: 635-654
   • Google Scholar
9. • Berenbaum MC
   What is synergy?.
   Pharmacol Rev. 1989; 41: 93-141
   • Google Scholar
10. • Chou T-C
    • Talalay P
    Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
    Adv Enzyme Regul. 1984; 22: 27-55
    • Google Scholar
11. • Chou T-C
    Relationships between inhibition constants and fractional inhibitions in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types of mechanisms of inhibition.
    Mol Pharmacol. 1974; 10: 235-247
    • Google Scholar
12. • Chou T-C
    Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands.
    J Theor Biol. 1996; 39: 253-276
    • Google Scholar
13. • Chou T-C
    • Talalay P
    Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.
    Eur J Biochem. 1981; 115: 207-216
    • Google Scholar
14. • Chou T-C
    • Talalay P
    Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents.
    in: Harrap KR Connors TA New Avenues of developmental cancer chemotherapy. 2nd ed. Bristol-Myers Symposium series. Academic Press, New York1987: 37-64
    • Google Scholar
15. • Chou J
    • Chou T-C
    Dose-effect analysis with microcomputers: quantitation of ED₅₀, LD₅₀, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics.
    in: Manual and software. Biosoft, Cambridge, England1987
    • Google Scholar
16. • Chou T-C
    • Hayball M
    CalcuSyn for Windows, multiple-drug dose-effect analyzer and manual.
    Biosoft, Cambridge, England1996
    • Google Scholar
17. • Loewe S
    Antagonism and antagonist.
    Pharmacol Rev. 1957; 9: 237-242
    • Google Scholar
18. • Berenbaum MC
    Synergy, additivism and antagonism in immunosupression: a critical review.
    Clin Exp Immunol. 1977; 28: 1-18
    • Google Scholar
19. • Webb JL
    2nd ed. Enzyme metabolic inhibitors. vol 1. Academic Press, New York1963: 55-79
    • Google Scholar
20. Science Citation Index. Institute for Scientific Information, Philadelphia1998 (1983–1998)
    • Google Scholar